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Abstract
Background: Acute kidney injury (AKI) occurs in more than half critically ill patients admitted in intensive care units
(ICU) and increases the mortality risk. The main cause of AKI in ICU is sepsis. AKI severity and other related variables
such as recurrence of AKI episodes may influence mortality risk. While AKI recurrence after hospital discharge has
been recently related to an increased risk of mortality, little is known about the rate and consequences of AKI
recurrence during the ICU stay. Our hypothesis is that AKI recurrence during ICU stay in septic patients may be
associated to a higher mortality risk.
Methods: We prospectively enrolled all (405) adult patients admitted to the ICU of our hospital with the diagnosis
of severe sepsis/septic shock for a period of 30 months. Serum creatinine was measured daily. ‘In-ICU AKI
recurrence’ was defined as a new spontaneous rise of ≥0.3 mg/dl within 48 h from the lowest serum creatinine
after the previous AKI episode.
Results: Excluding 5 patients who suffered the AKI after the initial admission to ICU, 331 patients out of the 400
patients (82.8%) developed at least one AKI while they remained in the ICU. Among them, 79 (19.8%) developed ≥2
AKI episodes.
Excluding 69 patients without AKI, in-hospital (adjusted HR = 2.48, 95% CI 1.47–4.19), 90-day (adjusted HR = 2.54,
95% CI 1.55–4.16) and end of follow-up (adjusted HR = 1.97, 95% CI 1.36–2.84) mortality rates were significantly
higher in patients with recurrent AKI, independently of sex, age, mechanical ventilation necessity, APACHE score,
baseline estimated glomerular filtration rate, complete recovery and KDIGO stage.
Conclusions: AKI recurred in about 20% of ICU patients after a first episode of sepsis-related AKI. This recurrence
increases the mortality rate independently of sepsis severity and of the KDIGO stage of the initial AKI episode. ICU
physicians must be aware of the risks related to AKI recurrence while multiple episodes of AKI should be
highlighted in electronic medical records and included in the variables of clinical risk scores.
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Background
Acute kidney injury (AKI) occurs in more than half crit-
ically ill patients admitted in intensive care units (ICU),
being sepsis and septic shock the main causes of AKI in
ICU patients [1, 2]. In the recently reported multi-
national AKI-EPI study, 57.3% of 1802 patients in ICU
developed AKI [1]. Patients affected by AKI present
higher risk of mortality, further chronic kidney disease
(CKD) and end-stage renal disease (ESRD) [1, 3–5] and
have a major impact on healthcare resources [6].
The important advance in AKI severity grading
achieved by recent definitions and classification systems
such as RIFLE, AKIN, KDIGO and creatinine kinetics
has allowed identifying a specific metrics in epidemi-
ology and outcome studies [7–10]. Furthermore, these
four classifications have demonstrated the relationship
between AKI severity and patient outcomes (mortality
and hospital length of stay) and have improved our
knowledge about AKI epidemiology [1, 11–15]. In these
circumstances, the identification of all the AKI-related
variables is quintessential to predict AKI occurrence, se-
verity and outcome.
In fact, AKI severity is not the only factor influencing
middle and long-term outcomes. Both AKI duration
and recurrence could influence morbidity, mortality
and healthcare cost associated to AKI. On the one
hand, several authors have suggested that the duration
of AKI is as important as severity with regard to out-
comes [16–18]. On the other hand, some studies have
demonstrated that AKI recurrence after hospital
discharge can take place up to 30% after the initial
AKI-related hospital admission and is associated to a
higher risk of mortality and CKD [19, 20]. Although,
currently no uniform definitions of AKI recovery and
recurrence exist, there is a growing interest in increas-
ing the knowledge about trajectories of recovery after
an AKI episode [21, 22]. In this sense, a consensus con-
ference was held in San Diego in 2015 focusing on
‘Persistent AKI and renal recovery’ [22]. Specifically, lit-
tle is known about the rate and consequences of AKI
recurrence during ICU and hospital stay. Our hypoth-
esis was that AKI recurrence in septic patients during
ICU stay is independently associated with mortality. To
contrast this hypothesis, our first aim was to determine
whether in-ICU AKI recurrence is an independent fac-
tor associated with mortality in comparison with
patients without AKI and with patients who only suf-
fered one AKI episode, showing a dose-response
pattern. The second aim was to address the importance
of AKI recurrence on the risk of mortality with inde-
pendence of severity (KDIGO stage) of the first AKI.
Last, our third objective was to determine the associ-
ation between AKI recurrence and mortality in patients
who recovered completely from their first AKI.
Methods
A prospective observational cohort study was carried
out in all patients (over 17 years of age) admitted to the
ICU—of ‘Marqués de Valdecilla’ University Hospital in
Santander (Spain)—with severe sepsis/septic shock ac-
cording to the definitions proposed by the SCCM/
ESICM/ACCP/ATS/SIS consensus conference (i.e. the
presence of arterial hypotension and/or persistent signs
of tissue hypoperfusion refractory to the intravenous
administration of fluids [20 ml/kg], and requiring the in-
fusion of vasoactive drugs) [23]. Enrollment occurred
from April 2008 to September 2010. Patients with
chronic kidney disease under renal replacement therapy
or who had received a kidney transplant were excluded.
Clinical and demographic characteristics of all patients,
including age, gender, previous diagnosis of hypertension,
diabetes mellitus, chronic obstructive pulmonary disease
(COPD), chronic heart failure (CHF) or cancer, immuno-
suppressive state (AIDS, neutropenia [neutrophil count
<1 × 109/L], exposure to glucocorticoids [>0.5 mg/kg for
>30 days] and/or immunosuppressive or cytotoxic
medications, solid organ transplantation, allogeneic or au-
tologous stem cell transplantation, haematological malig-
nancy or solid tumour), the source of infection, as well as
Acute Physiology and Chronic Health Evaluation II score
and Sequential Organ Failure Assessment score at ICU
admission, mechanical ventilation necessity, use of
vasopressors and length of ICU and hospital stay were re-
corded. Leukocyte number, lactate, C-reactive protein and
procalcitonin values were collected at ICU admission.
Serum creatinine was measured daily while the patients
were in ICU. Baseline serum creatinine was defined by the
most recent available value between 7 and 365 days before
hospital admission. Baseline glomerular filtration rate
(GFR) was estimated by 4-variable modification of diet in
renal disease (MDRD) equation [24]. In 16 (4%) patients
with no available baseline creatinine, it was calculated
from the simplified MDRD formula assuming a GFR of
75 ml/min per 1.73 m2 as recommended by the acute dia-
lysis quality initiative (ADQI) workgroup [7]. We defined
and staged AKI according to KDIGO serum creatinine cri-
teria [9]. In-ICU recurrent AKI was defined as a new
spontaneous rise of ≥0.3 mg/dl within 48 h from the low-
est serum creatinine after the previous AKI episode, with
partial or full recovery. We defined complete recovery
when the patient serum creatinine returned to base-
line creatinine or below. Partial recovery was defined
when the patient was off renal replacement therapy
and serum creatinine started to decrease after the
peak value but failed to return to baseline creatinine.
Rises of serum creatinine after renal replacement
therapy withdrawal were not defined as AKI recur-
rences. In-hospital and at 90-day mortality were
prospectively collected, and mortality at the end of
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follow-up was retrospectively collected in 2014, being
analysed as dependent variables.
Categorical variables were expressed as percentages
and continuous variables as median and interquartile
rank (IQR). Statistical differences between groups were
analysed by chi-square test or Fisher exact test when
appropriate for categorical variables, and the non-
parametric Mann-Whitney U test was used for continu-
ous variables.
We tested the equality of survival distributions for no
AKI, one AKI existence and AKI recurrence by using
the log-rank (Mantel-Cox) test and Kaplan-Meier sur-
vival curves. As KDIGO stage of the first AKI independ-
ently related to mortality, we additionally stratified by
KDIGO stage after excluding patients without AKI, test-
ing the equality of survival distributions for one AKI and
AKI recurrence in patients with KDIGO 2 and 3 stages
separately.
We estimated hazard ratios (HRs) to measure associ-
ations. We estimated adjusted HRs and their corre-
sponding 95% confidence intervals (95%CI) using
proportional hazards Cox regression models. We ad-
justed for the following variables: gender, age, mechan-
ical ventilation necessity, APACHE score and baseline
estimated GFR (ml/min/1.73 m2). When patients with-
out AKI were excluded from the analysis, KDIGO
stage and ‘complete recovery’ were also included in the
multivariable models. The alpha error was set at 0.05,
and all p values were two sided. We conducted all
statistical analyses using IBM SPSS Statistics version
22.0.
Results
Main characteristics of the 405 patients included in the
cohort are shown in Table 1. Mean follow-up was 956
(IQR 28–1662) days. Throughout the study, they were
no losses of follow-up during hospital stay. In 17 pa-
tients (4.25%), it was not possible a complete ‘follow-up’
up to 90 days after hospital discharge. In 25 patients, the
follow-up was <1 year, and in 33 patients, the follow-up
was <2 years. Five patients suffered AKI after the initial
admission in ICU due to sepsis, and they were excluded
from the analysis. Three hundred thirty-one patients out
of the 400 patients (82.8%) developed at least one in-
ICU acute kidney injury (AKI) according to KDIGO
classification. Among them, 72, 6 and 1 patients suffered
2, 3 and 4 AKI episodes, respectively, so 79 out of 400
patients (19.8%) developed recurrent AKI episodes dur-
ing their ICU stay. The flow chart of study population is
shown in Fig. 1.
Variables related to AKI recurrence are also shown in
Table 1. Patients with AKI recurrence were significantly
older and with lower baseline estimated GFR. APACHE
score was also higher. Crude mortality was 102/400
(25.5%) for in-hospital mortality, 110/400 (27.5%) at 90
days of follow-up and 188/400 (47%) at the end of
follow-up. Ninety-day survival was 59.3, 44.0, 86.7 and
55.3% for patients with partial recovery without AKI re-
currence, partial recovery with recurrence, complete re-
covery without recurrence and complete recovery with
recurrence, respectively.
In relation to our first objective, statistically significant
different survival distributions were observed when we
ordinal categorised ‘AKI existence’ into ‘patients without
any AKI episode’, ‘only one AKI’ and ‘two or more AKI
episodes (in-ICU recurrent AKI) (log rank p < 0.001)
(Fig. 2, Table 1). By Cox regression analysis, significant
dose-response patterns (adjusted p trends ≤0.021) were
also found. The greater the number of AKIs, the greater
the association for ‘intra-hospital’, ‘90 days’ and ‘end of
follow-up’ mortality, with independence of sex, age,
mechanical ventilation necessity, APACHE score and
baseline estimated GFR (Table 2).
KDIGO stage of the first AKI, independently related to
intra-hospital (adjusted HR per each increase of stage =
1.45, 95% CI 1.10–1.91), 90-day (adjusted HR per each
stage increase of severity = 1.31, 95% CI 1.01–1.71) and
end of follow-up mortality (adjusted HR per each in-
crease = 1.28, 95% CI 1.05–1.57).
Regarding our second objective, a specific analysis was
conducted with exclusion of non AKI patients, in order to
address the importance of AKI recurrence with independ-
ence also of severity of the first AKI. Excluding 69 patients
without AKI, in-hospital (adjusted HR 2.48, 95% CI 1.47–
4.19), 90-day (adjusted HR 2.54, 95% CI 1.55–4.16) and
end of follow-up (adjusted HR 1.97, 95% CI 1.36–2.84)
mortality rates were significantly higher in patients with
recurrent AKI, independently of the covariates above and
KDIGO stage and ‘complete recovery’ (Table 2). Restrict-
ing to patients with KDIGO 2 or 3 stages in the first AKI,
survival curves were also significantly lower for AKI recur-
rent patients in each KDIGO stage (log rank p < 0.001)
(Fig. 3).
In relation to our third objective, 243 patients out of
the 331 patients admitted in ICU due to sepsis with AKI
recovered completely from their initial AKI episode.
Analysing only this group of patients with complete re-
covery (N = 243), the recurrence of AKI remained as an
independent risk factor for further mortality at 90 days
(HR 3.21, 95% CI 1.74–5.92, p < 0.001) and at the end of
follow-up (data not shown in tables).
Discussion
The main finding of our study is that the development
of a new episode of AKI during ICU stay after the first
AKI episode related to sepsis is associated with a higher
mortality rate and increases the mortality rate. The mor-
tality risk rises more than double if the patient suffers
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from two or more AKI episodes during the same admis-
sion. Similarly, Siew et al. reported that patients admitted
to hospital with recurrent AKI—within 12 months of dis-
charge from the previous hospitalization with AKI—near
doubled the death rate [19]. It is known that diabetic
patients with AKI recurrence after previous hospital dis-
charge are at risk for stage 4 CKD. However, we did not
analyse residual renal function in our study [20]. Obvi-
ously, in our cohort, this increment in mortality comes up
after the first 5–10 days (Fig. 2) because AKI recurrence
Table 1 Baseline characteristic in all patients, and in relation to AKI recurrence risk
All patients No AKI Patients with in-ICU AKI
AKI = 1 AKI ≥2 (recurrent)
N = 405 N = 69 N = 252 N = 79 p value
Age (years), median [IQR] 68.21 [56.52–77.70] 55.84 [49.02–69.52] 69.28 [58.07–78.23] 74.29 [64.72–79.16] 0.027
Gender (male) 68.9% 56.5% 71.0% 72.2% 0.848
Hypertension 47.7% 27.5% 50.8% 58.2% 0.248
Diabetes mellitus 18.3% 4.3% 22.6% 17.9% 0.380
COPD 14.8% 13.0% 14.3% 19.0% 0.313
CHF 6.4% 4.3% 7.1% 6.3% 0.804
Cancer 13.6% 10.1% 13.9% 15.2% 0.773
Immunosuppressive state 17.8% 11.6% 19.4% 17.7% 0.734
Source of infection 0.122
Intra-abdominal 30.9% 29.0% 31.0% 32.9%
Lung 37.3% 52.2% 33.3% 35.4%
Endocarditis 0.5% 0.0% 0.0% 1.3%
Line related 1.5% 1.4% 2.0% 0.0%
Urinary tract 12.3% 8.7% 15.5% 6.3%
Skin and soft infection 2.0% 0.0% 2.0% 3.8%
Unknown/others 15.6% 8.7% 16.3%% 20.3%
Leukocytes, median [IQR] 13.60 [6.90–21.00] 12.6 [5.15–23.55] 13.60 [7.00–20.45] 15.50 [7.35–21.58] 0.441
Lactate (mg/dl), median [IQR] 23.0 [15.0–37.3] [–] 26.0 [16.0–41.0] 26.0 [17.0–47.0] 0.437
Vasopresors 84.3% 83.8% 85.6% 79.7% 0.214
Septic shock 85.4% 85.5% 86.4% 82.3% 0.366
APACHE, median [IQR] 20 [16–25] 16 [12–19] 20 [16–27] 23 [19–27] 0.032
SOFA, median [IQR] 8 [6–10] 7 [5–8] 9 [7–11] 9 [6–11] 0.952
Mechanical ventilation 51.1% 54.4% 49.4% 51.9% 0.699
C-reactive protein (mg/l), median [IQR] 19.4 [10.30–27.50] 18.6 [7.85–25.45] 20.4 [10.7–29.20] 18.3 [11.05–27.55] 0.673
Procalcitonin (ng/l), median [IQR] 10.24 [2.54–30.37] 4.11 [1.25–10.91] 13.11 [3.31–34.00] 13.29 [2.32–41.90] 0.749
Baseline creatinine (mg/dl), median [IQR] 0.97 [0.80–1.13] 0.88 [0.72–1.00] 0.95 [0.80–1.15] 1.05 [0.90–1.20] 0.022
Baseline estimated GFR (ml/min/1.73 m2), median [IQR] 72.50 [58.36–87.86] 81.91 [64.79–102.55] 72.74 [57.23–86.47] 66.18 [53.84–77.55] 0.030
ICU stay (days), median [IQR] 4.99 [2.99–11.47] 4.99 [1.99–8.48] 3.98 [2.99–10.97] 9.97 [4.99–17.95] <0.001
Hospital stay (days), median [IQR] 16.95 [10.22–30.92] 15.96 [10.97–32.41] 15.96 [9.97–28.92] 19.94 [13.96–34.90] 0.003
KDIGO AKI stages 0.054
1, n (%) 100 (24.7%) – 79 (31.3%) 21 (26.6%)
2, n (%) 121 (29.9%) – 98 (38.9%) 23 (29.1%)
3, n (%) 110 (27.2) – 75 (29.8%) 35 (44.3%)
Maximal creatinine (mg/dl), median [IQR] 2.10 [1.40–3.16] 1.00 [0.84–1.10] 2.30 [1.70–3.19] 2.99 [2.10–4.00] <0.001
Intra-hospital mortality, n (%) 104 (25.7%) 7 (10.1%) 60 (23.8%) 35 (44.3%) <0.001
90-day mortality, n (%) 112 (27.7%) 8 (11.6%) 64 (25.4%) 38 (48.1%) <0.001
End of follow-up mortality, n (%) 190 (46.9%) 22 (31.9%) 113 (44.8%) 53 (67.1%) 0.001
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takes some time to develop. As previously reported [15],
KDIGO stages of the first AKI episode are independently
related to mortality. Remarkably, using KDIGO serum
creatinine criteria to define AKI, we found that such small
elevations of creatinine as 0.3 mg/dl relate to a higher
mortality risk when they appear after a first AKI event and
this increment in mortality was independent of first epi-
sode KDIGO classification and severity of sepsis estimated
by APACHE score [9].
Moreover, we found that in-ICU AKI recurrence was
frequent, taking place in up to 20% of patients admitted
due to sepsis. It is expected that the rate of recurrence
after AKI related to different aetiologies should be lower
because sepsis is the most frequent AKI cause [1]. AKI
recurrence rate after hospital discharge is experienced
by 25–30% patients, although in-hospital AKI recurrence
rate has not been previously reported [19, 20]. In
addition, some patients suffered a third and a fourth in-
405 patients admitted in ICU due to sepsis 
• 5 AKI after sepsis admission 
• 69 no AKI 
331 patients admitted in ICU due to sepsis with AKI 
30 No recovery 
Peak Cr:  3.68 ± 2.01 
58 Partial recovery 
Peak Cr:  3.32 ± 1.79 
Lower Cr: 1.46 ± 0.65 
243 Complete recovery 
1º AKI length: 5, IQR 4-9 
Peak Cr: 2.61 ± 1.25 
Lower Cr: 0.86 ± 0.32 
33 No recurrent AKI 
Peak Cr:  3.21 ± 1.99 
Lower Cr: 1.48 ± 0.77  
189 No recurrent AKI 
1º AKI length: 5, IQR 4-9 
Peak Cr:  2.49 ± 1.25  
Lower Cr:  0.82 ± 0.28  
25 Recurrent AKI 
Peak Cr:  3.47 ± 1.51 
Lower Cr: 1.42 ± 0.47 
54 Recurrent AKI 
1º AKI length: 5, IQR 3.5-8 
Peak Cr: 3.02 ± 1.17 
Lower Cr: 1.02 ± 0.39 
Fig. 1 Flow chart of the study population. Abbreviations: ICU intensive care unit, AKI acute kidney injury, Cr serum creatinine, IQR interquartile range
Fig. 2 90-day survival curves including patients without AKI
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ICU AKI episode, which, in time, can even increase
more the risk of death, although we could not confirm
this case because only 7 patients developed so numerous
AKI episodes.
As pointed out by Siew et al., in order to prevent fur-
ther AKI recurrence, we need to identify patients at
highest recurrence risk [19]. Age and baseline estimated
GFR clearly related to a higher risk of recurrence in our
cohort study, and both are well-known risk factors for
AKI development [25]. By contrast, we did not find any
relationship between recurrence and gender or comorbid
risk factors (Table 2). Siew et al. reported that age, base-
line renal function and comorbid conditions such as
congestive heart failure, advanced liver disease, demen-
tia, diabetes and coronary artery disease were associated
with recurrent AKI after discharge for initial hospital ad-
mission in 11,683 patients [19]. On the one hand, the
lower number of patients included in our study can pre-
vent us from detecting the influence of these risk factors.
It is expected that older patients show more comorbid
Table 2 Hazard ratios for in-ICU AKI existence, in relation to mortality
Vital status (intra-hospital) Vital status (90-day) Vital status (end of follow-up)
Survival
(N)
Death
(N)
HR (95% CI) Survival
(N)
Death
(N)
HR (95% CI) Survival
(N)
Death
(N)
HR (95% CI)
Including patients without AKI (N = 400) 298 102 290 110 212 188
No AKI (n = 69) 62 7 1 – 61 8 1 – 47 22 1 –
AKI = 1 (n = 252) 192 60 1.68a 0.74 3.82 188 64 1.54a 0.71 3.34 139 113 1.00a 0.61 1.63
AKI ≥2 (n = 79) 44 35 2.73a 1.15 6.51 41 38 2.57a 1.13 5.83 26 53 1.61a 0.93 2.77
Linear p trend 0.006 0.005 0.021
Excluding patients without AKI (N = 331) 236 95 229 102 165 166
AKI = 1 (n = 252) 192 60 1 – 188 64 1 – 139 113 1 –
AKI ≥2 (n = 79) 44 35 2.48b 1.47 4.19 41 38 2.54b 1.55 4.16 26 53 1.97b 1.36 2.84
aHR = hazard ratio adjusted for sex, age, mechanical ventilation necessity, APACHE score, and baseline estimated glomerular filtration rate (GFR)
bHR = hazard ratio adjusted for sex, age, mechanical ventilation necessity, APACHE score, baseline estimated GFR, complete recovery and KDIGO stage
Fig. 3 90-day survival curves as a function of KDIGO stages, excluding patients without AKI and restricting to patients with KDIGO 2 or 3 stages
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conditions that can place them at a higher risk for AKI
recurrence. On the other hand, all our patients devel-
oped the first AKI episode due to sepsis and this can
limit the influence of other comorbid risk factors.
In our study, severity of sepsis estimated by Sequential
Organ Failure Assessment (SOFA), number of
leukocytes, lactate, C-reactive protein, procalcitonin and
use of vasopressors did not relate to AKI recurrence.
Conversely, the severity of the first AKI episode was as-
sociated with a higher AKI recurrence as well as severity
of sepsis as assessed by APACHE score. Although with-
out reaching statistical significance, 44% patients with
in-ICU recurrence had previously suffered a KDIGO
stage 3 AKI episode, whereas only 30% patients without
recurrence had shown a similar AKI stage. Maximal cre-
atinine in the first AKI episode and baseline estimated
GFR were also higher in patients with further recur-
rence. In this sense, older patients admitted in ICU due
to sepsis, with higher APACHE scores and worse renal
function and a more severe AKI episode can be identi-
fied as at a higher rate of AKI recurrence in our cohort.
The main advantage of our study was that we defined
KDIGO stages and AKI recurrence analysing one-by-one
daily creatinine for each patient. For example, a rise of
creatinine ≥0.3 mg/dl after the initial AKI episode was
only considered AKI recurrence when the previous AKI
episode was recovering and not when it was due to con-
tinuous or intermittent renal replacement therapy with-
drawal. AKI recurrence can be hard to record unless
prospectively reported in the medical history of the
patient or in electronic databases. Due to the association
of AKI recurrence with mortality rate, we suggest that
the ICU physicians must be aware to its risk and add
this diagnosis in the clinical records and registers to-
gether with the AKI index episode.
Our study has several limitations. First, we performed a
single-centre study and the number of patients included
was not high enough to detect the influence of several risk
factors previously related to AKI [19, 25]. Whereas one of
the advantages of multicentre studies is the high number
of patients that can be enrolled, studies carried out in sin-
gle centres are more homogeneous with respect to inclu-
sion criteria and type of care of the patients. In our case,
all patients were included if they fulfilled severe sepsis/
septic shock definition according to the SCCM/ESICM/
ACCP/ATS/SIS consensus conference [23].
Second, we lost to follow up 4.25% of patients at
90 days because our ICU is part of a tertiary care hos-
pital and some of these patients were discharged to dif-
ferent healthcare systems. We cannot rule out that this
rate of follow-up losses had an impact on the reported
results, but meaningfully, all the patients were followed
up throughout the whole hospital admission until ‘death’
or ‘discharge home’ and there were no in-hospital losses.
Third, we did not use urine output to define AKI. Al-
though urine volume rate is part of the AKI definition
[9], most AKI staging studies are based on serum cre-
atinine levels alone and do not include urine output data
[26]. The course of ICU stay in patients with sepsis
should be closely monitored in order to detect recurrent
episodes of AKI [27–29].
Conclusions
To conclude, we performed a single-centre observational
study and detected that AKI can recur in up to 20% of pa-
tients who suffer a sepsis-related AKI during the initial
hospital admission episode. This recurrence is associated
with a higher mortality rate independently of several co-
variates such as initial AKI and sepsis severity, and the as-
sociation between AKI recurrence and mortality seems to
be also present in patients who recovered completely from
their first AKI. If these findings are confirmed in larger
subsequent multicenter studies, it may be advisable for
ICU physicians to be aware of AKI recurrence risk and to
add the number of AKI episodes along with their severity
and duration in clinical and electronic records to establish
the global influence of AKI episodes on patient outcome.
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